PG I Rapid Quantitative Test Kit IFA Colloidal Gold CE Approval IVD
Blood Diagnostic
Phosphoglucose isomerase (glucose-6-phosphate isomerase or PGI, EC
5.3.1.9) is an important housekeeping enzyme. PGI catalyzes the
interconversion of glucose-6- phosphate to fructose-6-phosphate.
PGI performs multiple functions & intracellularly plays key role in
both glycolysis and gluconeogenesis. Extracellularly, PGI [also
called Autocrine Motility Factor (AMF)] functions as a cytokine,
which stimulates cell motility and is associated with tumor
development and metastasis. In humans, PGI deficiency causes
hemolytic anemia, whereas increased PGI activity is observed in
many cancers such as gastrointestinal, kidney and breast cancer.
Early detection of abnormal phosphoglucose isomerase activity is
crucial for diagnosis, prediction and therapeutic strategy.
About NIR-1000 Dry Fluoroimmunoassay Analyser
It is a fluorescence immunochromatographic analysing system with
internal temperature control,
which can help diagnose conditions such as infection, diabetes,
cardiovascular diseases, renal injury and cancers, etc.
Immunofluorescence technology
Testing time less than 15 minutes
Easy-to-use touch-screen platform,multi-language system
Note:
1) Any variation in operator, pipetting and washing technique,
incubation time or temperature, and kit age can cause variation in
result. Each user should obtain their own standard curve.
2) If samples have been diluted, the concentration read from the
standard curve must be multiplied by the dilution factor.
3) If specimens generate values higher than the highest standard,
dilute the specimens and repeat the assay
| Assay list | Tumor Marker | | | | |
| cat#. | Product item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
| 20 | AFP | Serum/Plasma | 15min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
| 21 | CEA | Serum/Plasma | 15min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
| 22 | NSE | Serum/Plasma | 15min. | 1-400ng/ml | <16ng/ml | non-small cell lung cancer |
| 23 | FOB | fecal specimens | 10min. | 50-1000ng/ml | <100ng/ml | Abnormal recessive gastrointestinal bleeding |
| 24 | PG II | Serum/Plasma | 15min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
| 25 | PG I | Serum/Plasma | 15min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
| 26 | TPSA | Serum/Plasma | 15min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
| 27 | FPSA | Serum/Plasma | 15min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
| 28 | CA12-5 | Serum/Plasma | 15min. | 20-500U/ml | <35U/ml | ovarian cancer |
| 29 | CA15-3 | Serum/Plasma | 15min. | 10-400U/ml | < 25 U/mL | breast cancer |
| 30 | HE4 | Serum/Plasma | 15min. | 50-2000pmol/L | <140 pmol/L | ovarian cancer |
| 31 | CA19-9 | Serum/Plasma | 15min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
| 32 | β-HCG | Serum/Plasma | 15min. | 5-400mIU/ml | <10 mIU/mL | Early pregrancy, ectopic HCG cancer,incomplete abortion |
| 33 | CK19(Cyfra21-1) | Serum/Plasma | 15min. | 0.5-50ng/ml | <2.5ng/ml | non-small cell lung cancer |
